Clinical Trials & Research Studies in Canada(Updated 8/25)

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631

Recruiting

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

Gender:

MALE

Ages:

45 years and above

Trial Updated:

01/29/2025

Locations: Georgia Cancer Center at Augusta University, Augusta, Georgia +53 locations

Georgia Cancer Center at Augusta University, Augusta, Georgia

University of Kansas Medical Center, Kansas City, Kansas

Westmead Hospital, Westmead, New South Wales

Royal Adelaide Hospital, Adelaide, South Australia

Flinders Medical Center, Adelaide, South Australia

Centro de Pesquisa Clínica do Brasil, Brasilia, DF

Hospital Felício Rocho, Belo Horizonte, Minas Gerais

Universidade Federal do Triângulo Mineiro, Uberaba, Minas Gerais

Sociedade Hospitalar Angelina Caron, Campina Grande Do Sul, Paraná

Nucleo de Pesquisa Clinica Hospital do Rocio, Campo Largo, Paraná

Centro Médico São Francisco, Curitiba, Paraná

Instituto De Medicina Integral Prof. Fernando Figueira - IMIP, Recife, Pernambuco

Hospital de Caridade de Ijuí, Ijuí, Rio Grande do Sul

Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul

Irmandade Da Santa Casa De Misericórdia De Porto Alegre, Porto Alegre, Rio Grande do Sul

Hospital Mae de Deus, Porto Alegre, Rio Grande Do Sul

Hospital Municipal de Barueri, Barueri, Sao Paulo

Faculdade de Medicina da Universidade Estadual Paulista - Campus de Botucatu - UNESP, Botucatu, São Paulo

Hospital Universitário São Francisco na Providência de Deus, Bragança Paulista, São Paulo

Fundacao Doutor Amaral Carvalho, Jaú, São Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José Do Rio Preto, São Paulo

Integral Pesquisa e Ensino, Votuporanga, São Paulo

Instituto Nacional de Cardiologia, Rio De Janeiro, Not set

Santa Casa de São Paulo (IPITEC), São Paulo, Not set

Hospital Alemao Oswaldo Cruz, São Paulo, Not set

Beneficência Nipo-Brasileira de São Paulo. Hospital Nipo-Brasileiro, São Paulo, Not set

Marina Leonardo, São Paulo, Not set

Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and Fundação Zerbini (Incor), São Paulo, Not set

Hospital Santa Marcelina, São Paulo, Not set

Instituto D'Or de Pesquisa e Ensino, São Paulo, Not set

Vancouver General Hospital, Vancouver, British Columbia

St. Joseph's Healthcare, Hamilton, Ontario

Juravinski Cancer Centre, Hamilton, Ontario

Queen's University, Kingston, Ontario

Grand River Hospital, Grand River Regional Cancer Centre, Kitchener, Ontario

London Health Sciences Centre, London, Ontario

London Health Sciences, Victoria Hospital, London, Ontario

Niagara Health, St. Catharines Site, Niagara, Ontario

Ottawa Hospital Research Institute, Ottawa, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario

University Hospital of Montreal, Montreal, Quebec

Jewish General Hospital, Montreal, Quebec

Hopital Maisonneuve-Rosemont, Montréal, Quebec

McGill University, Montréal, Quebec

Laval University, Quebec City, Quebec

Centre Universitaire de Sherbrooke, Sherbrooke, Quebec

Hospital Universitario San Ignacio, Bogotá, Cundinamarca

FOSCAL, Floridablanca, Santander

Fundacio Valle de Lili, Cali, Valle del Cauca

Heart Institute - Holon Medical Center, Holon, Not set

Rabin Medical Center, Petach Tikva, Not set

Tel-Aviv Sourasky Medical Centre, Tel Aviv, Not set

Istanbul University, Istanbul, Not set

Conditions: Prostate Cancer, Cardiovascular Disease

Register for Updates

Learn More ›

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

NCT03433274

Recruiting

Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate t... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Princeton Baptist Medical Center, Birmingham, Alabama +79 locations

Princeton Baptist Medical Center, Birmingham, Alabama

UAB University Hospital, Birmingham, Alabama

Banner-University Medical Center, Phoenix, Arizona

HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona

Baptist Health Medical Center, Little Rock, Arkansas

Fresno Heart Hospital, Fresno, California

University of Southern California University Hospital, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

Sutter Medical Center, Sacramento, Sacramento, California

University of California - Davis Medical Center, Sacramento, California

San Diego Cardiac Center, San Diego, California

University of California at San Francisco, San Francisco, California

Stanford Health Care, Stanford, California

Los Robles Hospital and Medical Center, Thousand Oaks, California

University of Colorado Hospital, Aurora, Colorado

Manatee Memorial Hospital, Bradenton, Florida

Morton Plant Hospital, Clearwater, Florida

Delray Medical Center, Delray Beach, Florida

North Florida Regional Medical Center, Gainesville, Florida

Shands at the University of Florida, Gainesville, Florida

Baptist Hospital of Miami, Miami, Florida

Tallahassee Research Institute, Tallahassee, Florida

Cleveland Clinic Florida, Weston, Florida

Piedmont Heart Institute, Atlanta, Georgia

Emory University Hospital, Atlanta, Georgia

Wellstar Kennestone Hospital, Marietta, Georgia

St. Alphonsus Regional Medical Center, Boise, Idaho

Rush University Medical Center, Chicago, Illinois

Advocate Christ Medical Center, Oak Lawn, Illinois

Prairie Education & Research Cooperative, Springfield, Illinois

St. Vincent Hospital, Indianapolis, Indiana

Cardiovascular Research Institute of Kansas, Wichita, Kansas

MedStar Health Research Institute, Balitmore, Maryland

University of Maryland Medical Center, Baltimore, Maryland

Adventist HealthCare White Oak Medical Center, Silver Spring, Maryland

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Henry Ford Hospital, Detroit, Michigan

Beaumont Hospital, Royal Oak, Michigan

Abbott Northwestern Hospital, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

St. Luke's Hospital, Kansas City, Missouri

St. Louis University Hospital, Saint Louis, Missouri

The International Heart Institute of Montana, Missoula, Montana

Catholic Medical Center, Manchester, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Robert Wood Johnson University Hospital, New Brunswick, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

Albany Medical College at Albany Medical Center, Albany, New York

South Shore University Hospital, Bay Shore, New York

Buffalo General Hospital, Buffalo, New York

New York Presbyterian Hospital/ Weill Cornell Medical Center, New York, New York

Lenox Hill Hospital, New York, New York

Mission Health & Hospitals, Asheville, North Carolina

Carolinas Medical Center, Charlotte, North Carolina

Novant Health Heart and Vascular Research Institute, Charlotte, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

The Cleveland Clinic Foundation, Cleveland, Ohio

Oklahoma Heart Institute at Utica, Tulsa, Oklahoma

Providence Heart & Vascular Institute, Portland, Oregon

Allegheny General Hospital - ASRI, Pittsburgh, Pennsylvania

UPMC Shadyside, Pittsburgh, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Baptist Memorial Hospital, Memphis, Tennessee

Centennial Medical Center, Nashville, Tennessee

St. Thomas Hospital, Nashville, Tennessee

Cardiothoracic & Vascular Surgeons, Austin, Texas

Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas

Medical City Dallas Hospital, Dallas, Texas

Memorial Hermann Hospital, Houston, Texas

University of Virginia Medical Center, Charlottesville, Virginia

Inova Fairfax Hospital, Falls Church, Virginia

Swedish Medical Center - Heart & Vascular, Seattle, Washington

West Virginia University Hospital, Morgantown, West Virginia

Medical College of Wisconsin, Milwaukee, Wisconsin

Ottawa Heart Institute, Ottawa, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

St. Michael's Hospital, Toronto, Ontario

The Royal Victoria Hospital, Montreal, Quebec

Institut de Cardiologie de Montreal (Montreal Heart Institute), Montréal, Quebec

Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease

Register for Updates

Learn More ›

Effect of Erector Spinae (ESP) Block on Opioid Reduction and Enhanced Recovery After Posterior Cervical Spine Surgery

NCT04646707

Recruiting

Patients undergoing spine surgery frequently experience significant pain after surgery. This can limit patient activity and hinder rehabilitation. If inadequately treated, severe pain can result in emotional and psychological distress and ultimately impact long-term function, and increase the risk of developing pain that lasts longer than six months associated with depression, anxiety and disability. More specifically, Erector Spinae Plane (ESP) block is a recently described plane block designe... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

01/29/2025

Locations: Toronto Western Hospital?UHN, Toronto, Ontario

Conditions: Postoperative, Pain

Register for Updates

Learn More ›

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350

Recruiting

A randomized controlled trial to evaluate AGN1 to prevent secondary hip fractures in osteoporotic women undergoing treatment of index hip fractures. Up to 2400 subjects will be randomized between a treatment group and a control group. Subjects will be followed for a minimum of 5 years after undergoing hip fracture repair surgery.

Gender:

FEMALE

Ages:

65 years and above

Trial Updated:

01/29/2025

Locations: Innsbruck Hospital, Innsbruck, Not set +53 locations

Innsbruck Hospital, Innsbruck, Not set

Health Sciences Centre - Eastern Health, Saint John's, Newfoundland and Labrador

Aarhus University Hospital, Aarhus, Not set

CHU Grenoble-Alpes, Grenoble, Not set

CHU Lyon, Lyon, Not set

CHU Toulouse, Toulouse, Not set

University Hospital of Duesseldorf, Düsseldorf, Not set

Justus Liebig Universitat Gießen, Gießen, Not set

Medizinische Hochschule Hannover, Hannover, Not set

Universitatsklinikum Schleswig-Holstein, Kiel, Not set

Klinikum der Universität München, München, Not set

University Hospital of Münster, Münster, Not set

Universitätsklinikum Regensburg, Regensburg, Not set

BG Klinik Tuebingen, Tuebingen, Not set

Helios Wuppertal, Wuppertal, Not set

Azienda Ospedaliero Universitaria Careggi, Firenze, Not set

ASST Gaetano Pini CTO, Milano, Not set

University Hospital San Raffaele Milano, Milano, Not set

Policlinico Tor Vergata, Rome, Not set

CTO Torino, Torino, Not set

Akita City Hospital, Akita-shi, Akita

Southern Tohoku General Hospital, Kōriyama, Fukushima

Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo

Kagawa Rosai Hospital, Marugame, Kagawa

Kanto Rosai Hospital, Kawasaki City, Kanagawa

Shin-yurigaoka General Hospital, Kawasaki-Shi, Kanagawa

Chikamori Hospital, Kouchi City, Kochi

Okayama Medical Center, Okayama City, Okayama

Jutendo University Shizuoka Hospital, Izunokuni City, Shizuoka

The University of Tokyo Hospital, Bunkyō-Ku, Tokyo

St. Mary's Hospital, Fukuoka, Not set

Iwata City Hospital, Iwata, Not set

Shin-Yurigaoka General Hospital, Kawasaki-shi, Not set

National Hospital Organization Kumamoto Medical Center, Kumamoto, Not set

Saga-Ken Medical Centre Koseikan, Saga, Not set

Japanese Red Cross Shizuoka Hospital, Shizuoka, Not set

Deventer Hospital, Deventer, Not set

Saint Anna Ziekenhuis, Geldrop, Not set

Maastricht UMC, Maastricht, Not set

Isala Hospital, Zwolle, Not set

Vall d'Hebron University Hospital, Barcelona, Not set

Clinic de Barcelona, Barcelona, Not set

Hospital Universitario de Basurto, Bilbao, Not set

Galdakao-Usansolo Hospital, Galdakao, Not set

Hospital Neuro-Traumatológico de Jaén, Jaén, Not set

Hospital Clínico San Carlos, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

PARC Tauli, Sabadell, Not set

Mutua de Terrassa University Hospital, Terrassa, Not set

Valladolid University Clinic Hospital, Valladolid, Not set

Birmingham Heartlands Hospital, Birmingham, England

Leicester Royal Infirmary, Leicester, England

Royal Infirmary of Edinburgh, Edinburgh, Scotland

Nottingham University Hospitals, Queen's Medical Center, Nottingham, Not set

Conditions: Fragility Fracture, Hip Fractures, Osteoporosis

Register for Updates

Learn More ›

Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study

NCT04962672

Recruiting

Cancer is a leading cause of death worldwide. It is estimated that approximately 55,000 Canadians are surviving with brain tumors. It is projected that around 3000 persons will be diagnosed with brain and spinal cord tumors, and approximately 75 percent patients will not survive. Out of all brain cancers, high-grade gliomas \[Glioblastoma Multiforme (GBM)\] impose highest morbidity and mortality. Therefore, it is important to explore ways in which Investigators can improve and prolong the lives... Read More

Cancer is a leading cause of death worldwide. It is estimated that approximately 55,000 Canadians are surviving with brain tumors. It is projected that around 3000 persons will be diagnosed with brain and spinal cord tumors, and approximately 75 percent patients will not survive. Out of all brain cancers, high-grade gliomas \[Glioblastoma Multiforme (GBM)\] impose highest morbidity and mortality. Therefore, it is important to explore ways in which Investigators can improve and prolong the lives of patients suffering from brain cancers, particularly high-grade glioma, which is the most common and aggressive primary brain tumor. So far the Investigators know that the surgery, chemotherapy and radiotherapy are the three corner stones management options for these patients, and majority of the research have been conducted on these three major domains. Therefore, it is imperative to explore the other variables those may impact survival characteristics. One of the integral variables of the brain cancer surgery is anesthesia. Interestingly, the role of anesthetics was explored in some other non-brain solid organ tumor surgeries. It is observed that out of the two main types of anesthesia \[one is through intravenous (propofol) and other one is gaseous (sevoflurane)\], intravenous based anesthesia maintenance regime may delay the cancer progression and prolong the recurrence free period. In addition, two very large retrospective studies with approximately 11,000 and 18,000 patients respectively, showed that as compared to gaseous (volatile anesthetics) based, intravenous (propofol) based anesthesia conferred some protection against cancer progression and was also associated with lesser overall mortality. The exact nature of these protective mechanisms is not known but in animal and other laboratory-based experiments, propofol seems to inhibit cancer formation steps, delays inflammation and provide protection from cancer cell growth. This is a feasibility study for knowing various aspects of workflow; recruitment characteristics of participants and various obstacles in implying anesthesia based protocols so that the Investigators can conduct a well-designed multicenter international randomized study. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Toronto Western Hospital/UHN, Toronto, Ontario

Conditions: Anesthesia, Brain Cancer, Survival

Register for Updates

Learn More ›

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

NCT05388149

Recruiting

This is a Phase 2 study for patients with resected Stage I-III HER2+ breast cancer with detected molecular residual disease (MRD+) following standard neoadjuvant and locoregional therapy delivered with curative intent. In this study Patients will be treated with neratinib in addition to their standard T-DM1 adjuvant therapy. Neratinib will be administered orally at a dose of 160 mg daily for up to 12 months, or until the time of clinical recurrence, discontinuation due to toxicity, or withdrawal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: University Health Network: Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Breast Cancer, HER2-positive Breast Cancer

Register for Updates

Learn More ›

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

NCT05403177

Recruiting

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Kingston Health Sciences Centre, Kingston, Ontario +2 locations

Conditions: Breast Cancer, Colorectal Cancer, Pancreas Cancer, Kidney Cancer, Prostate Cancer, Ovary Cancer, Head and Neck Cancer, Leukemia, Lymphoma, Lung Cancer, Melanoma, Solid Tumor

Register for Updates

Learn More ›

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

NCT05715814

Recruiting

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Toronto General Hospital, Toronto, Ontario

Conditions: Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction, Residual Kidney Function

Register for Updates

Learn More ›

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

NCT05938712

Recruiting

The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Toronto General Hospital, Toronto, Ontario

Conditions: Kidney Transplant Recipients

Register for Updates

Learn More ›

Minimally Displaced Femoral Neck Fracture Pilot Study

NCT05947058

Recruiting

The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy minimally displaced femoral neck fracture (FNF) treated with surgery will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, hip arthroplasty or internal fixation. Participants will be followed for 1 year.

Gender:

ALL

Ages:

60 years and above

Trial Updated:

01/29/2025

Locations: University of Southern California, Los Angeles, California +10 locations

Conditions: Femoral Neck Fractures

Register for Updates

Learn More ›

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

NCT05994976

Recruiting

The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Innovaderm Research Inc., Montréal, Quebec

Conditions: Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa, Plaque Psoriasis, Palmoplantar Pustulosis

Register for Updates

Learn More ›

High Heated Humidity in Stem Cell Transplant

NCT05358262

Recruiting

The purpose of this study is to find out what effects of high heated humidity has on you and your mucositis.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/28/2025

Locations: Cross Cancer Institute, Edmonton, Alberta

Conditions: Autologous Stem Cell Transplant

Register for Updates

Learn More ›

All Clinical Trials in Canada

Match to Clinical Trials